Simultaneous Activation of Kras and Inactivation of p53 Induces Soft Tissue Sarcoma and Bladder Urothelial Hyperplasia

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Yang, Xiaoping ^a,b   La Rosa, Francisco G ^a,b   Genova, Elizabeth Erin ^a   Huber, Kendra ^a   Schaack, Jerome ^a   DeGregori, James ^a,b   Serkova, Natalie J ^a,b   Li, Yuan ^a,c   Su, Lih Jen ^a   Kessler, Elizabeth ^a   Flaig, Thomas W ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CRE RECOMBINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE INACTIVATION; HYPERPLASIA; MOUSE; NONHUMAN; ONCOGENE K RAS; SOFT TISSUE SARCOMA; SPINDLE CELL SARCOMA; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; UROTHELIAL HYPERPLASIA;

ADENOVIRIDAE; ANIMALS; BETA-GALACTOSIDASE; BREEDING; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENOTYPE; HYPERPLASIA; INTEGRASES; KERATINS; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; ORGAN SPECIFICITY; PROTO-ONCOGENE PROTEINS P21(RAS); REPRODUCIBILITY OF RESULTS; RNA, UNTRANSLATED; SARCOMA; STAINING AND LABELING; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER; UROTHELIUM;

EID: 84884220500     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074809     Document Type: Article

References (54)

1. DuPage M, Dooley AL, Jacks T, (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4: 1064-1072. doi:10.1038/nprot.2009.95. PubMed: 19561589.
2. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, et al. (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410: 1111-1116. doi:10.1038/35074129. PubMed: 11323676.
3. Herbst RS, Heymach JV, Lippman SM, (2008) Lung cancer. N Engl J Med 359: 1367-1380. doi:10.1056/NEJMra0802714. PubMed: 18815398.
4. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483. doi:10.1016/j.ccr.2005.04.023. PubMed: 15894267.
5. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, et al. (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149: 656-670. doi:10.1016/j.cell.2012.01.058. PubMed: 22541435.
6. Collins MA, Bednar F, Zhang Y, Brisset JC, Galbán S, et al. (2012) Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 122: 639-653. doi:10.1172/JCI59227. PubMed: 22232209.
7. Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
8. Uchida T, Wada C, Ishida H, Wang C, Egawa S, et al. (1995) p53 mutations and prognosis in bladder tumors. J Urol 153: 1097-1104. doi:10.1016/S0022-5347(01)67517-7. PubMed: 7869472.
9. Williamson MP, Elder PA, Knowles MA, (1994) The spectrum of TP53 mutations in bladder carcinoma. Genes Chromosomes Cancer 9: 108-118. doi:10.1002/gcc.2870090206. PubMed: 7513540.
10. Goebell PJ, Knowles MA, (2010) Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 28: 409-428. doi:10.1016/j.urolonc.2010.04.003. PubMed: 20610279.
11. Knowles MA, (1995) Molecular genetics of bladder cancer. Br J Urol 75 (Suppl 1):: 57-66. PubMed: 7613858.
12. Orntoft TF, Wolf H, (1998) Molecular alterations in bladder cancer. Urol Res 26: 223-233. doi:10.1007/s002400050050. PubMed: 9759995.
13. Gao J, Huang HY, Pak J, Cheng J, Zhang ZT, et al. (2004) p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Oncogene 23: 687-696. doi:10.1038/sj.onc.1207169. PubMed: 14737103.
14. Uchida T, Wada C, Ishida H, Egawa S, Ao T, et al. (1995) Infrequent involvement of mutations on neurofibromatosis type 1, H-ras, K-ras and N-ras in urothelial tumors. Urol Int 55: 63-67. doi:10.1159/000282753. PubMed: 8533197.
15. Olderøy G, Daehlin L, Ogreid D, (1998) Low-frequency mutation of Ha-ras and Ki-ras oncogenes in transitional cell carcinoma of the bladder. Anticancer Res 18: 2675-2678. PubMed: 9703927.
16. Ayan S, Gokce G, Kilicarslan H, Ozdemir O, Yildiz E, et al. (2001) K-RAS mutation in transitional cell carcinoma of urinary bladder. Int Urol Nephrol 33: 363-367. doi:10.1023/A:1015213713048. PubMed: 12092657.
17. Ahmad I, Singh LB, Foth M, Morris CA, Taketo MM, et al. (2011) K-Ras and beta-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Dis Model. J Mech 4: 548-555.
18. Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, et al. (2011) Ras mutation cooperates with beta-catenin activation to drive bladder tumourigenesis. Cell Death. Drosophila Inf Serv 2: e124.
19. Knudson AG Jr., (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68: 820-823. doi:10.1073/pnas.68.4.820. PubMed: 5279523.
20. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, et al. (2004) Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5: 375-387. doi:10.1016/S1535-6108(04)00085-6. PubMed: 15093544.
21. Raimondi AR, Molinolo A, Gutkind JS, (2009) Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res 69: 4159-4166. doi:10.1158/0008-5472.CAN-08-4645. PubMed: 19435901.
22. Quintanilla M, Brown K, Ramsden M, Balmain A, (1986) Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322: 78-80. doi:10.1038/322078a0. PubMed: 3014349.
23. Kühn R, Torres RM, (2002) Cre/loxP recombination system and gene targeting. Methods Mol Biol 180: 175-204. PubMed: 11873650.
24. Frese KK, Tuveson DA, (2007) Maximizing mouse cancer models. Nat Rev Cancer 7: 645-658. doi:10.1038/nri2136. PubMed: 17687385.
25. Mo L, Cheng J, Lee EY, Sun TT, Wu XR, (2005) Gene deletion in urothelium by specific expression of Cre recombinase. Am J Physiol Renal Physiol 289: F562-F568. doi:10.1152/ajprenal.00368.2004. PubMed: 15840768.
26. Bian Y, Terse A, Du J, Hall B, Molinolo A, et al. (2009) Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res 69: 5918-5926. doi:10.1158/0008-5472.CAN-08-4623. PubMed: 19584284.
27. Hayashi S, McMahon AP, (2002) Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol 244: 305-318. doi:10.1006/dbio.2002.0597. PubMed: 11944939.
28. Bex A, Vooijs M, Horenblas S, Berns A, (2002) Controlling gene expression in the urothelium using transgenic mice with inducible bladder specific Cre-lox recombination. J Urol 168: 2641-2644. doi:10.1016/S0022-5347(05)64235-8. PubMed: 12442001.
29. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, et al. (2009) Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 23: 675-680. doi:10.1101/gad.1772909. PubMed: 19261747.
30. Soriano P, (1999) Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 21: 70-71. doi:10.1038/5007. PubMed: 9916792.
31. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243-3248. doi:10.1101/gad.943001. PubMed: 11751630.
32. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, et al. (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29: 418-425. doi:10.1038/ng747. PubMed: 11694875.
33. Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, et al. (2013) Diphtheria Toxin-Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer. Clin Cancer Res 19: 148-157. doi:10.1158/1078-0432.CCR-12-1258. PubMed: 23172881.
34. Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, et al. (2007) A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 13: 992-997. doi:10.1038/nm1602. PubMed: 17676052.
35. Iatropoulos MJ, Williams GM, (1996) Proliferation markers. Exp Toxicol Pathol 48: 175-181. doi:10.1016/S0940-2993(96)80039-X. PubMed: 8672872.
36. Thanan R, Murata M, Ma N, Hammam O, Wishahi M, et al. (2012) Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer. Mediat Inflamm(2012): pp. 165879. PubMed: 22577245.
37. Daniluk J, Liu Y, Deng D, Chu J, Huang H, et al. (2012) An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 122: 1519-1528. doi:10.1172/JCI59743. PubMed: 22406536.
38. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, et al. (2003) Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4: 181-189. doi:10.1016/S1535-6108(03)00220-4. PubMed: 14522252.
39. Anderson RD, Haskell RE, Xia H, Roessler BJ, Davidson BL, (2000) A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 7: 1034-1038. doi:10.1038/sj.gt.3301197. PubMed: 10871752.
40. Schaack J, Bennett ML, Colbert JD, Torres AV, Clayton GH, et al. (2004) E1A and E1B proteins inhibit inflammation induced by adenovirus. Proc Natl Acad Sci U S A 101: 3124-3129. doi:10.1073/pnas.0303709101. PubMed: 14976240.
41. Evans RK, Nawrocki DK, Isopi LA, Williams DM, Casimiro DR, et al. (2004) Development of stable liquid formulations for adenovirus-based vaccines. J Pharmacol Sci 93: 2458-2475. doi:10.1002/jps.20157. PubMed: 15349956.
42. Akagi K, Sandig V, Vooijs M, Van der Valk M, Giovannini M, et al. (1997) Cre-mediated somatic site-specific recombination in mice. Nucleic Acids Res 25: 1766-1773. doi:10.1093/nar/25.9.1766. PubMed: 9108159.
43. Orlicky DJ, Degala G, Greenwood C, Bales ES, Russell TD, et al. (2008) Multiple functions encoded by the N-terminal PAT domain of adipophilin. J Cell Sci 121: 2921-2929. doi:10.1242/jcs.026153. PubMed: 18697835.
44. Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, et al. (2006) Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68: 549-553. doi:10.1016/j.urology.2006.03.062. PubMed: 16979735.
45. Malmström PU, (2011) Bladder tumours: time for a paradigm shift? BJU Int 107: 1543-1545. doi:10.1111/j.1464-410X.2011.10235.x. PubMed: 21518416.
46. Yang X, Flaig TW, (2010) Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application. Int Braz J Urol 36: 273-282. doi:10.1590/S1677-55382010000300003. PubMed: 20602819.
47. Chan E, Patel A, Heston W, Larchian W, (2009) Mouse orthotopic models for bladder cancer research. BJU Int 104: 1286-1291. doi:10.1111/j.1464-410X.2009.08577.x. PubMed: 19388981.
48. Jonkers J, Berns A, (2002) Conditional mouse models of sporadic cancer. Nat Rev Cancer 2: 251-265. doi:10.1038/nrc777. PubMed: 12001987.
49. Ahmad I, Morton JP, Singh LB, Radulescu SM, Ridgway RA, et al. (2011) beta-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene 30: 178-189. doi:10.1038/onc.2010.399. PubMed: 20818428.
50. Deng CX, Xu X, (2004) Generation and analysis of Brca1 conditional knockout mice. Methods Mol Biol 280: 185-200. PubMed: 15187254.
51. Bindels EM, van den Brekel MW, (2005) Development of a conditional mouse model for head and neck squamous cell carcinoma. Adv Otorhinolaryngol 62: 1-11. PubMed: 15608413.
52. Gilbert PM, Havenstrite KL, Magnusson KE, Sacco A, Leonardi NA, et al. (2010) Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science 329: 1078-1081. doi:10.1126/science.1191035. PubMed: 20647425.
53. Hicks RM, (1975) The mammalian urinary bladder: an accommodating organ. Biol Rev Camb Philos Soc 50: 215-246. doi:10.1111/j.1469-185X.1975.tb01057.x. PubMed: 1100129.
54. He F, Mo L, Zheng XY, Hu C, Lepor H, et al. (2009) Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res 69: 9413-9421. doi:10.1158/0008-5472.CAN-09-2158. PubMed: 19951992.